

Executive Officer Notice: Supplying of Publicly Funded Evusheld™ for Pre-Exposure Prophylaxis of COVID-19 in Ontario Pharmacies

Effective October 3, 2022

All pharmacies with a Health Network System (HNS) account and valid HNS Subscription Agreement with the ministry (hereinafter referred to as “pharmacy” or “pharmacies”) are eligible to dispense the publicly funded monoclonal antibody Evusheld™ (tixagevimab and cilavimab) for prevention of COVID-19 to eligible Ontarians.

This Executive Officer (EO) Notice and the accompanying Questions and Answers (Qs & As) document set out the terms and conditions for a pharmacy’s submission of claims for payment (claims) for supplying Evusheld™ to eligible individuals. This Notice and Qs & As are a Ministry Policy that pharmacy operators must comply with under section 3.2 of the HNS Subscription Agreement for Pharmacy Operators.

General Eligibility

An individual with a valid prescription for Evusheld™ is eligible to receive publicly funded Evusheld™ if:

- they live, work, or study in Ontario or they are visiting Ontario from another province/territory or country, and
- they meet the applicable clinical criteria (see section below).

Note that an eligible individual does not need to be an Ontario Drug Benefit Program recipient and may not have a valid Ontario health number¹ (e.g., if they are visiting Ontario from another province/territory or country). If a pharmacy supplies publicly funded

¹ In this Executive Officer Notice and the accompanying Qs & As, “Ontario health number” means Ontario Health Insurance Plan (OHIP) Card Number or Ontario Drug Benefit (ODB) eligibility number issued by the Ministry of Children, Community and Social Services or by a Home and Community Care Support Service organization for some ODB eligible recipients.

Evusheld™ to an eligible individual who does not have a valid Ontario health number, then the pharmacy must submit the claim for payment using the Proxy ID (see billing procedures below).

Clinical Criteria

The clinical criteria for the dispensing of Evusheld™ is based on the provincial [clinical guidance](#) for the pre-exposure prophylaxis of COVID-19 infection.

To be eligible for publicly funded Evusheld™, individuals must:

- Be 12 years of age or older;
- Weigh at least 40 kg;
- Not have a current COVID-19 infection;
- Not have a recent COVID-19 exposure*; AND
- Be immunocompromised, have the highest risk of having an inadequate immune response to vaccination, and belong to one or more of the following groups:
 - solid organ transplant recipients
 - stem cell transplant recipients
 - CAR-T therapy recipients
 - other hematologic cancer patients undergoing treatment
 - individuals receiving anti-B-cell therapy (e.g., rituximab)
 - individuals with significant primary immunodeficiency

* Recent exposure means that the individual has had contact with a confirmed case and is still within the timeframe to develop COVID-19 from that exposure (e.g., 8 days). Refer to [clinical guidance](#) for more information.

General Description

- There is **no cost** to eligible individuals who receive publicly funded Evusheld™ at a pharmacy.
- No drug cost will be paid as pharmacies will receive Evusheld™ free-of-charge through participating pharmaceutical distributors.
- Table 1 lists the dispensing fees paid to pharmacies for supplying publicly funded Evusheld™ products to eligible individuals².

² Inclusion of a product in the Table does not guarantee supply of the product through the participating pharmaceutical distributors.

- Eligible individuals may receive a 300mg or 600mg dose of Evusheld™ as prescribed. Please ensure to use the correct PIN in claims for payment.

Table 1: PINs to Support Reimbursement for Supplying Publicly Funded Evusheld™ (tixagevimab and cilavimab)

PIN	Description	Total Amount Paid*
09858167	Evusheld Dispensing Fee – 300mg dose (includes \$13.25 dispensing fee and distribution costs for one unit)	\$23.25
09858169	Evulsheld Dispensing Fee – 600mg dose ³ (includes \$13.25 dispensing fee and distribution costs for two units)	\$33.25

*Note: Primary pharmacy service providers of long-term care (LTC) homes are reimbursed through the LTC home capitation model and will not be paid a dispensing fee for supplying publicly funded Evusheld™ to a LTC home resident who is an eligible individual. Except in emergency situations, secondary pharmacy service providers (i.e., those that do not have a contract with a LTC home) are also not eligible for a dispensing fee for supplying publicly funded Evusheld™ to a LTC home resident who is an eligible individual. Pharmacies ineligible to receive a dispensing fee must submit claims for Evusheld™ with a zero dollar fee.

Billing Procedures – Summary

- Claims for supplying Evusheld™ can only be submitted electronically using the HNS (see “Billing Procedures - Detailed” below). No manual paper claims will be accepted unless 3 intervention codes are required in order to process the claim.
- Each claim must include one of the Product Identification Numbers (PINs) noted in Table 1 above (do not use the DIN of the product).
- The person submitting the claim must ensure that the eligible individual’s date of birth, Ontario health number (if available) and name (as it appears on the health card, if available) are included in the claim. Failure to do so – especially for non-

³ The Health Canada approved Product Monograph for Evusheld™ includes a recommended dose of 300mg, but indicates that a 600mg dose may be considered in certain circumstances. Some prescribers may exercise their clinical judgment and prescribe a 600mg dose. Dispensers are encouraged to review the Product Monograph and to consult with the prescriber if they have any questions or concerns about a prescribed dosage.

Ontario Drug Benefit (ODB) Program recipients – may impact the ability to submit future claims for these individuals.

- **For eligible individuals without an Ontario health number, pharmacies must use the proxy patient ID: 79999 999 93 (see below for further details).**

Billing Procedures – Detailed

Claims submission requirements are as follows:

For ODB-eligible recipients

The claim submission follows the usual process (See [Section 5](#) of the Ontario Drug Programs Reference Manual (“Manual”)) for submitting claims on the HNS with the following additional information:

- Intervention code ‘PS’: (Professional Care Services)
- PIN: see Table 1 above for list of PINs
- Valid Pharmacist ID
- Professional Fee: see Table 1 above for ‘Total Amount Paid’

For Non-ODB recipients

When submitting a claim for an eligible individual who does not have ODB coverage, pharmacists must submit the following information:

- Patient Gender: ‘F’ = female; ‘M’ = male
- Patient Date of Birth: Valid YYYYMMDD
- Patient’s Ontario Health number*
- Intervention codes:
 - PS: Professional Care Services
 - ML: Established eligibility coverage (i.e., 1 day of the Plan ‘S’ coverage)
- Carrier ID: ‘S’
- PIN: see Table 1 above for list of PINs
- Valid Pharmacist ID
- Professional Fee: see Table 1 above for ‘Total Amount Paid’

***For eligible individuals without an Ontario health number**

When submitting a claim for an eligible person who does not have an Ontario health number, pharmacists must submit the following information:

- First Name: Patient’s first name
- Last Name: Patient’s last name
- Patient Gender: ‘F’ = female; ‘M’ = male
- Patient Date of Birth: Valid YYYYMMDD
- **Proxy patient ID: 79999 999 93**
- Intervention codes:
 - PS: Professional Care Services
 - PB: Name entered is consistent with card
- Valid Pharmacist ID

Pharmacy Documentation Requirements

Pharmacies must keep a record of every publicly funded Evusheld™ product supplied to an eligible individual. Standard documentation requirements for prescriptions apply.

Pharmacies and pharmacists shall keep records consistent with their obligations under applicable law, including the *Pharmacy Act, 1991* and the *Drug and Pharmacies Regulation Act*, and under any instructions or guidelines provided by the Ontario College of Pharmacists or the ministry.

For purposes of post-payment verification, pharmacy records related to claims for publicly funded Evusheld™ must be maintained in a readily available format for the purpose of ministry inspection for a minimum of 10 years from the last recorded pharmacy service provided to the eligible individual, or until 10 years after the day on which the individual reached or would have reached the age of 18 years, whichever is longer.

Overpayments due to inappropriate claim submissions are subject to recovery.

The following pharmacy documentation must be maintained in a readily retrievable format for the purposes of post-payment verification:

- A copy of the prescription for Evusheld™; and
- A written record made by the dispenser that the individual meets the eligibility criteria for publicly funded Evusheld™ including:
 - Screening the individual to ensure they are not currently symptomatic or known to be infected with COVID-19; however a COVID-19 test is not required to receive Evusheld™. The individual must also be screened to ensure they have no recent high-risk exposure to a confirmed or probable

case of COVID-19 during the close contact’s period of communicability as defined in the clinical guidance.

- A written record that the individual was provided with proper instructions for use including storage requirements and information regarding potential side effects.

Exclusions and Restrictions

- Publicly funded Evusheld™ can only be supplied to an eligible individual pursuant to a valid prescription.
- Administration of non-publicly funded Evusheld™ that is privately purchased by the pharmacy does not qualify for payment of a dispensing fee.
- Only a single claim (with one dispensing fee) is eligible for reimbursement per recipient according to the recommended dosing guidelines regardless of whether 300mg or 600mg of Evusheld™ is dispensed. The PIN corresponding to the dose of Evusheld™ dispensed must be used.
- If an eligible individual does not have a valid Ontario health number, publicly funded Evusheld™ can still be dispensed, provided that the individual provides an alternate identification confirming their name and date of birth. In such cases, pharmacies must use the **proxy patient ID: 79999 999 93**.
- The supply of publicly funded Evusheld™ for an eligible individual who is a resident of a Long-Term Care (LTC) home falls under the LTC capitation funding model and must be provided by the LTC home’s contracted primary pharmacy service provider. A LTC home primary pharmacy service provider is not eligible for a dispensing fee under this policy for supplying publicly funded Evusheld™ to residents of the LTC home who are eligible individuals. Except in emergency situations, secondary pharmacy service providers (i.e. those that do not have a contract with a LTC home) are not eligible for a dispensing fee for supplying publicly funded Evusheld™ to LTC home residents who are eligible individuals. Pharmacies not eligible for a dispensing fee must submit claims for Evusheld™ with a zero dollar fee.

Additional Information:

For pharmacy billing: Please call ODB Pharmacy Help Desk at: 1-800-668-6641

For COVID-19 related issues in pharmacy: Please email the ministry at: OPDPInfoBox@ontario.ca

For COVID-19 treatment information: Please access this [website](#)

For Ministry COVID-19 Information and Planning Resources

- For vaccines, please access this [website](#)
- For guidance, please access this [website](#)

For all other Health Care Providers and the Public: Please call ServiceOntario, Infoline at 1-866-532-3161 TTY 1-800-387-5559. In Toronto, TTY 416-327-4282.